Intellihealth Review

Intellihealth — Provider Profile

Overview

Intellihealth is an obesity medicine telehealth platform built primarily for health systems, employers, and payers rather than individual consumers. Founded in 2019, the company's core model is B2B2C: they partner with health systems and large employers to deliver board-certified obesity medicine care at scale, integrating with existing healthcare infrastructure rather than operating as a standalone consumer app. Patients who access Intellihealth through a health system partnership often have their care documented within the same electronic health record they use for their other providers, which is a meaningful clinical advantage.

The clinical team is staffed by physicians who hold board certification from the American Board of Obesity Medicine (ABOM). This certification requires demonstrated expertise in obesity medicine beyond general prescribing, including behavioral interventions, pharmacology, and the management of weight-related comorbidities. In a market crowded with platforms where GLP-1 prescriptions are issued after short async questionnaires, ABOM certification represents a higher clinical bar and a different philosophy toward care.

As of early 2026, the direct-to-consumer availability of Intellihealth for patients without an employer or health system pathway is limited. The company's go-to-market focus is institutional rather than retail, which makes it less accessible than DTC platforms but more likely to coordinate with a patient's existing medical team. Patients whose employers or health systems partner with Intellihealth receive a meaningfully different experience from what most GLP-1 telehealth platforms offer.

Medications Offered

• Semaglutide (Wegovy, Ozempic) — brand-name, FDA-approved
• Tirzepatide (Zepbound, Mounjaro) — brand-name, FDA-approved
• Additional anti-obesity medications as clinically indicated under obesity medicine specialist oversight
• Medication management integrated with behavioral support

Note: Compounded semaglutide lost its FDA shortage exemption in February 2025. Compounded tirzepatide is subject to FDA 503B enforcement beginning April 2026. Intellihealth's clinical model focuses on FDA-approved brand-name medications under specialist supervision.

Pricing

Intellihealth does not publish straightforward retail pricing because direct-to-consumer enrollment is not the primary access model. Medication costs are separate from the consultation/care fees and depend on pharmacy benefits. If your employer offers Intellihealth through benefits, the program cost is typically low or zero. Verify current pricing and access pathways at intellihealth.com.

States Served

Intellihealth operates across multiple U.S. states through health system and employer partnerships. Direct-to-consumer geographic availability may differ from institutional availability. Confirm your state and access pathway at intellihealth.com.

Insurance

• Accessed primarily through employer benefits and health system partnerships
• Commercial insurance accepted in many cases depending on partnership
• Medication coverage depends on individual pharmacy benefits
• Not primarily a self-pay / out-of-pocket platform for individual consumers

Consultation Process

Model: Video consultations with board-certified obesity medicine physicians, integrated with health system EHR where applicable

1. Access through employer benefits portal or health system referral
2. Initial intake including medical history, labs review, and BMI/comorbidity assessment
3. Video consultation with ABOM-certified obesity medicine specialist
4. Personalized treatment plan including medication selection, behavioral goals, and follow-up schedule
5. Regular follow-up visits for medication titration and progress review
6. Care coordination with patient's existing primary care physician where relevant

Pros

• Board-certified obesity medicine physicians — higher clinical standard than most GLP-1 telehealth platforms
• Integration with health systems means care is documented in the patient's main medical record
• Evidence-based obesity medicine protocols rather than symptom-and-prescription transactional model
• Institutional backing provides clinical oversight and accountability often absent from DTC platforms
• Better positioned to manage complex patients with multiple comorbidities
• Treats obesity as a chronic disease requiring ongoing management, not a one-time prescription event

Cons

• Difficult or impossible to access without an employer or health system partnership — low DTC availability
• Not designed for patients seeking fast, self-directed access to GLP-1 medications
• Geographic availability limited by institutional partnerships rather than physician licensure alone
• Less consumer-friendly onboarding compared to DTC telehealth platforms
• Pricing transparency is poor for individual consumers trying to evaluate options
• Not suitable for patients whose employers haven't contracted with Intellihealth

Best For

Intellihealth is best suited for patients who have access through an employer benefits program or a partnered health system and want their weight management care managed by a board-certified obesity medicine specialist integrated with their existing healthcare record. It is particularly well-suited for patients with complex medical histories, multiple comorbidities, or prior unsuccessful weight loss attempts who need more clinical depth than a standard GLP-1 telehealth platform provides.

Editorial Verdict

Intellihealth's value proposition is genuine but narrowly accessible. For patients who can reach it through institutional pathways, the combination of ABOM-certified physicians and health system integration is a real clinical advantage. Obesity medicine board certification matters — it means the prescribing physician has demonstrated knowledge of how anti-obesity medications interact with comorbidities, when behavioral interventions should precede or accompany pharmacotherapy, and how to manage long-term weight maintenance rather than just initial loss.

The access problem is significant, however. If your employer doesn't offer Intellihealth and your health system doesn't partner with them, you're likely unable to use the platform as an individual consumer. This limits its relevance as a comparison option for most patients doing independent research. For those who do have access, the institutional model — where care is documented, coordinated, and supervised within a clinical framework — is meaningfully superior to the episodic, siloed care typical of DTC GLP-1 platforms.

In a market where GLP-1 prescriptions are increasingly commoditized, Intellihealth is doing something harder: delivering obesity medicine care that fits inside the larger healthcare system rather than operating parallel to it. The B2B model creates real access friction for individual patients, but the underlying clinical approach — coordinated, documented, specialist-supervised — is the more defensible one.

Related Content

• Who Qualifies for GLP-1 Medications?
• How Much Does Semaglutide Cost?
• How Much Does Tirzepatide Cost?